Vantia Limited
Drug Discovery Company
Website
www.vantiatherapeutics.com/
Contact Name
Mr. Andy Crockett
Company Position
Chief Executive Officer
Contact Email
info@vantiatherapeutics.com
Contact Address
Southampton Science Park
1 Venture Road
Chilworth
Southampton
SO16 7NP
UK
Contact Phone
+44 23 8076 3400
Latest News
2nd February 2010
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia
Read this article
More News
6th October 2009
Vantia Therapeutics announces that its novel oral small molecule drug for the treatment of dysmenorrhoea has entered Phase II proof-of-concept trials
Read this article
29th June 2009
Vantia Therapeutics announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia.
Read this article
20th March 2008
Vantia Therapeutics, a new UK-based R&D company, has been launched with backing from an investor syndicate led by MVM Life Science Partners, along with SV Life Sciences and Novo A/S.
Read this article
Vantia Therapeutics is a research based healthcare company dedicated to improving clinical treatments through development and commercialisation of innovative medicines. Founded on Ferring Research's 21 year experience in small molecule discovery & early development, Vantia was formed in late 2007 and acquired a series of drug assets and people from Ferring in March 2008. The Company is based on Southampton University's Science Park at Chilworth in the UK.
Vantia's lead assets are VT483, a vasopressin agonist in Phase II clinical trials for the treatment of nocturia and VT913, a vasopressin antagonist for the treatment of dysmennhorrea scheduled to enter human trials in 2008. In addition, Vantia has a discovery pipeline focused on serine protease targets, including inhibitors of kallikrein and FAP. These agents will be developed for the treatment of inflammatory and fibrotic conditions.
